CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
PF-04971729 is a selective sodium-dependent glucose cotransporter (SGLT) inhibitor which selectively targets SGLT2.
More Information
Supplier Page
CSNpharm
PF-04971729 is a selective sodium-dependent glucose cotransporter (SGLT) inhibitor which selectively targets SGLT2.
More Information
Supplier Page
CSNpharm
PF-04971729 is a selective sodium-dependent glucose cotransporter (SGLT) inhibitor which selectively targets SGLT2.
More Information
Supplier Page
CSNpharm
PF-04971729 is a selective sodium-dependent glucose cotransporter (SGLT) inhibitor which selectively targets SGLT2.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM.
More Information
Supplier Page
CSNpharm
PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM.
More Information
Supplier Page
CSNpharm
PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM.
More Information
Supplier Page
CSNpharm
PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM.
More Information
Supplier Page
CSNpharm
PF-06928215 is a cyclic GMP-AMP synthase (cGAS) inhibitor with IC50 of 4.9 μM in the presence of 1 mM ATP, 0.3 mM GTP, 100 nM 45-bp interferon-stimulatory dsDNA (ISD).
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
PF-9366 is an allosteric inhibitor of Mat2A that binds an allosteric site on Mat2A that overlaps with the binding site for the Mat2A regulator, Mat2B, targeting S-adenosylmethionine biosynthesis, with IC50 of 420 nM and Kd of 170 nM, respectively.
More Information
Supplier Page
CSNpharm
PF-9366 is an allosteric inhibitor of Mat2A that binds an allosteric site on Mat2A that overlaps with the binding site for the Mat2A regulator, Mat2B, targeting S-adenosylmethionine biosynthesis, with IC50 of 420 nM and Kd of 170 nM, respectively.
More Information
Supplier Page
CSNpharm
PF-9366 is an allosteric inhibitor of Mat2A that binds an allosteric site on Mat2A that overlaps with the binding site for the Mat2A regulator, Mat2B, targeting S-adenosylmethionine biosynthesis, with IC50 of 420 nM and Kd of 170 nM, respectively.
More Information
Supplier Page
CSNpharm
PF-9366 is an allosteric inhibitor of Mat2A that binds an allosteric site on Mat2A that overlaps with the binding site for the Mat2A regulator, Mat2B, targeting S-adenosylmethionine biosynthesis, with IC50 of 420 nM and Kd of 170 nM, respectively.
More Information
Supplier Page
CSNpharm
PF-9366 is an allosteric inhibitor of Mat2A that binds an allosteric site on Mat2A that overlaps with the binding site for the Mat2A regulator, Mat2B, targeting S-adenosylmethionine biosynthesis, with IC50 of 420 nM and Kd of 170 nM, respectively.
More Information
Supplier Page
CSNpharm
PF-9366 is an allosteric inhibitor of Mat2A that binds an allosteric site on Mat2A that overlaps with the binding site for the Mat2A regulator, Mat2B, targeting S-adenosylmethionine biosynthesis, with IC50 of 420 nM and Kd of 170 nM, respectively.
More Information
Supplier Page
PFI-1
10mg
| ≥98%
CSNpharm
PFI-1 is a highly selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM and for BRD2 with IC50 of 98 nM in a cell-free assay.
More Information
Supplier Page
PFI-1
5mg
| ≥98%
CSNpharm
PFI-1 is a highly selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM and for BRD2 with IC50 of 98 nM in a cell-free assay.
More Information
Supplier Page
PFI-1
100mg
| ≥98%
CSNpharm
PFI-1 is a highly selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM and for BRD2 with IC50 of 98 nM in a cell-free assay.
More Information
Supplier Page
PFI-1
1mg
| ≥98%
CSNpharm
PFI-1 is a highly selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM and for BRD2 with IC50 of 98 nM in a cell-free assay.
More Information
Supplier Page
PFI-1
50mg
| ≥98%
CSNpharm
PFI-1 is a highly selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM and for BRD2 with IC50 of 98 nM in a cell-free assay.
More Information
Supplier Page
CSNpharm
PFI-2 HCl is an a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 with IC50 of 2 nM, 500 fold active than (S)-PFI-2.
More Information
Supplier Page
CSNpharm
PFI-2 HCl is an a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 with IC50 of 2 nM, 500 fold active than (S)-PFI-2.
More Information
Supplier Page
CSNpharm
PFI-2 HCl is an a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 with IC50 of 2 nM, 500 fold active than (S)-PFI-2.
More Information
Supplier Page
CSNpharm
PFI-2 HCl is an a first-in-class, potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 with IC50 of 2 nM, 500 fold active than (S)-PFI-2.
More Information
Supplier Page
PFI-3
50mg
| ≥99%
CSNpharm
PFI-3
5mg
| ≥99%
CSNpharm
PFI-3
10mg
| ≥99%
CSNpharm
PFI-4
10mg
| ≥98%
CSNpharm
PFI-4
5mg
| ≥98%
CSNpharm
PFI-4
100mg
| ≥98%
CSNpharm
PFI-4
50mg
| ≥98%
CSNpharm